

Non-Executive Director Fee Benchmarking

Summary of Mercer Report dated 16 June 2023

Fisher & Paykel Healthcare Corporation Limited

Introduction

Mercer has been engaged by Fisher & Paykel Healthcare Corporation Limited (FPH or the "Company") to provide independent remuneration benchmarking data for its Non-Executive Directors (NEDs) against publicly listed companies comparable to FPH.

In particular, FPH has requested Mercer to:

- Recommend and provide a rationale for a relevant set of comparator companies;
- Determine non-executive director remuneration at the comparator companies, including remuneration for committee membership;
- · Report on our findings; and
- Provide a summary report to be made available publicly for review by shareholders and proxy advisors.

Approach

Mercer's approach to this engagement was as follows:

- Gathered current information on FPH's Board and Committee structure, workload commitments and current remuneration arrangements for all Board and Committee roles included in the review referencing information provided and FPH's public disclosures.
- Worked with FPH to review and finalise a Listed Peer Group of companies listed on New Zealand Exchange (NZX) and the Australian Securities Exchange (ASX).
- Extracted and reviewed available board fee data sourced from the Listed Peer Group, and compared FPH's practices against the collated market data.

© Mercer Consulting (Australia) Pty Ltd ACN 153 168 140.

This document has been prepared solely for the client to whom it is addressed, for its internal use for the purpose stated in this document. It contains confidential and proprietary information of Mercer and it is not to be distributed more widely without the prior permission of Mercer. Mercer and its employees do not accept responsibility to any third party for anything in or arising out of the material and information herein, and it is not intended that any third party should rely on such material.

- Provided relevant commentary in regards to Mercer's observations of FPH's position against the
 market, including potential changes to FPH's board fee structure and the resultant impacts on the
 aggregate fee pool.
- Prepared a report outlining our approach, findings and recommendations.

Please see Appendix A for more information in regards to our benchmarking methodology.

Listed Peer Group

In establishing an appropriate comparator dataset, Mercer has worked with FPH to review and finalise a **Listed Peer Group** of companies. The diagram below shows the filtering process adopted in shortlisting the benchmarking peer group.



The final list of 9 NZX and 10 ASX listed companies is presented in the table below. FPH's market capitalisation and revenue positioning against the Listed Peer Group is provided at the bottom of the table. All financial data is presented in New Zealand Dollars unless otherwise indicated and has been sourced from S&P Capital IQ as at 31 March 2023.

| Company Name | Primary Listing Country | Market Capitalisation (6-months to 31 March 2023) (\$'000,000s) | Most Recent Year- End Revenue (\$'000,000s) |
|----------------------------|----------------------------|---|---|
| WiseTech Global Limited | Australia | 20,195 | 700 |
| REA Group Limited | Australia | 17,436 | 1,580 |
| Sonic Healthcare Limited | Australia | 16,425 | 10,340 |
| Ramsay Health Care Limited | Australia | 15,792 | 14,738 |
| Cochlear Limited | Australia | 15,087 | 1,825 |
| Meridian Energy Limited | New Zealand | 13,032 | 3,703 |

Page 3
Non-Executive Director Fee Benchmarking – Summary Report
Fisher & Paykel Healthcare Corporation Limited
16 June 2023

| Company Name | Primary Listing Country | Market Capitalisation (6-months to 31 March 2023) (\$'000,000s) | Most Recent Year- End Revenue (\$'000,000s) | |
|--|----------------------------|---|---|--|
| Xero Limited | Australia | 12,387 | 1,097 | |
| Auckland International Airport Limited | New Zealand | 11,955 | 291 | |
| TPG Telecom Limited | Australia | 9,824 | 5,806 | |
| Spark New Zealand Limited | New Zealand | 9,661 | 3,720 | |
| SEEK Limited | Australia | 8,645 | 1,236 | |
| carsales.com Ltd | Australia | 8,241 | 564 | |
| EBOS Group Limited | New Zealand | 8,046 | 11,883 | |
| Mercury NZ Limited | New Zealand | 8,041 | 2,188 | |
| Mainfreight Limited | New Zealand | 7,098 | 5,218 | |
| Pro Medicus Limited | Australia | 6,706 | 104 | |
| Infratil Limited | New Zealand | 6,275 | 861 | |
| Contact Energy Limited | New Zealand | 5,937 | 2,387 | |
| The a2 Milk Company Limited | New Zealand | 5,002 | 1,444 | |
| Fisher & Paykel Healthcare Corporation Limited | New Zealand | 13,307 | 1,682 | |
| Percent Rank | | 71% | 47% | |
| 75th Percentile | | 15,087 | 5,218 | |
| Median | | 9,661 | 1,825 | |
| 25th Percentile | | 7,098 | 861 | |
| Average | | 10,831 | 3,668 | |


Benchmarking Outcomes

Positioning of FPH's Board Chair Fee and NED Base Fee against the Listed Peer Group

The diagram below presents the comparison of FPH's base policy fees against the selected Listed Peer Group.

- FPH's Board Chair fee is positioned at the 25th percentile of Listed Peer Group.
- FPH's NED Base Fee is positioned at the 25th percentile of Listed Peer Group.

Page 4 Non-Executive Director Fee Benchmarking – Summary Report Fisher & Paykel Healthcare Corporation Limited 16 June 2023



FPH Fee Pool versus the Listed Peer Group

The diagram below present the comparison of FPH's approved maximum aggregate NED fee pool to the Listed Peer Group.



Page 5 Non-Executive Director Fee Benchmarking – Summary Report Fisher & Paykel Healthcare Corporation Limited 16 June 2023

Additionally, Mercer notes the following:

- Based on the current fee structure, FPH total fee spend is \$1,421,494, which represents 97.7% of the current approved fee pool.
- Mercer has analysed the fee pool headroom for NZX companies within the peer group and found that the average headroom was 13.6%.
 - We note that the largest headroom was 22.5% and the smallest headroom was 5.1%. This suggests that FPH's headroom is currently lower than all of the NZX companies in the Listed Peer Group.
 - In Mercer's experience, a fee pool headroom of 20%-25% is typical for ASX-listed companies.
- The average "age" of the fee pool amongst the NZX companies within the peer group is 2.6 years.

Summary of FPH's positioning

FPH's positioning against the Listed Peer Group is summarised in the table below.

| Fee Element | | | FPH's Positioning vs Listed Peer Group | | |
|-------------------|-----------------|--------------------------------|--|--|--|
| Board | Chair Fee | | At the 25th percentile | | |
| Fees | Member Base Fee | | At the 25th percentile | | |
| Committee Fees | Chair | Audit and Risk Committee | Slightly below the 25th percentile | | |
| | Member | Addit and Risk Committee | Between the 25 th percentile and the median | | |
| | Chair | People and Remuneration | At the 25th percentile | | |
| | Member | Committee | Between the median and the 75th percentile | | |
| | Chair | Quality, Safety and Regulatory | At the median | | |
| | Member | Committee | Above the median | | |
| NED Fee Pool | | | At the 25th percentile | | |
| Number of NEDs | | | At the median | | |

Recommendations

Considerations in Determining a Target Market Position

In preparing our recommendations for FPH's proposed fees, we have proposed the median of the Listed Peer Group as an appropriate target market position given the below considerations:

- FPH's market capitalisation and revenue positioning being at the 71st and 47th percentile respectively.
- The workload of the FPH Board and Committees compared to the Listed Peer Group.

Recommended Adjustments to FPH's Policy Fees

Mercer's recommended changes to FPH's policy fees is presented in the table below.

| Role | Current | Ratio of Chair to Member Fees | Proposed | Ratio of Chair to Member Fees | % Change | |
|--|-------------|--|-------------|--|-------------|--|
| Main Board | | | | | | |
| Board Chair Fee | \$287,897 | | \$324,000 | | 12.5% | |
| Member Base Fee | \$137,222 | 2.10x | \$144,000 | 2.25x | 4.9% | |
| Audit & Risk Committee | | | | | | |
| Chair Fee | \$34,978 | | \$37,900 | | 8.4% | |
| Member Fee | \$18,950 | 1.85x | \$18,950 | 2.00x | 0.0% | |
| People & Remuneration Committee | | | | | | |
| Chair Fee | \$26,906 | | \$33,163 | | 23.3% | |
| Member Fee | \$18,950 | 1.42x | \$18,950 | 1.75x | 0.0% | |
| Quality, Safety & Regulatory Committee | | | | | | |
| Chair Fee | \$25,249 | | \$28,425 | | 12.6% | |
| Member Fee | \$18,950 | 1.33x | \$18,950 | 1.50x | 0.0% | |
| Maximum Fee Pool | | | | | | |
| Suggested aggregate fee pool | \$1,455,000 | | \$1,750,000 | | 20.3% | |

Key parameters considered in the proposed changes include:

 Retaining FPH's approach to paying an overseas director allowance to non-New Zealand based directors. Page 7
Non-Executive Director Fee Benchmarking – Summary Report
Fisher & Paykel Healthcare Corporation Limited
16 June 2023

- Benchmark policy fees to the median inclusive of the overseas director allowance. Given the nature
 of the peer group being comprised of half Australian companies, the inclusion of the overseas
 director's allowance would provide a more complete picture of FPH's competitiveness.
- Retaining current committee member fees and adjusting committee chair fees to better reflect market relativities between chair and member fees for each committee within the Listed Peer Group.
- Setting the aggregate fee pool of \$1,750,000 to provide a headroom of approximately 15% consistent
 with the practices observed amongst NZX companies. This headroom is intended to act as a buffer
 for FPH to respond to any additional workload resulting from any potential changes in FPH's board
 structure or any special circumstances for the next three years.

The proposed policy fees will broadly position FPH at the median of the Listed Peer Group consistent with the target positioning discussed above.

Statement of Independence

In providing advice to FPH, Mercer has adopted these Global Business Standards for Board and Remuneration Advisory Services to manage actual or perceived conflicts of interest and to preserve the integrity of our advice. The Global Business Standards address how we (i) manage the executive rewards consulting relationship, (ii) ensure the quality of executive rewards consulting services and (iii) structure our business to manage actual or perceived conflicts of interest.



In providing advice on FPH's non-executive director remuneration arrangements, David Yong (Engagement Lead) has exercised professional judgment without being unduly influenced by any personal, financial, or professional relationships that could compromise the objectivity of the advice provided.

Page 8
Non-Executive Director Fee Benchmarking – Summary Report
Fisher & Paykel Healthcare Corporation Limited
16 June 2023

Mercer also confirms that there are no conflicts of interest that could impair the integrity of the advice provided. In particular, David Yong has not been engaged in any activity that could create a conflict of interest, either directly or indirectly, with the interests of FPH or its stakeholders.

Appendix A: Benchmarking Methodology

Market data presented

- Policy fee data has been extracted from the most recent annual report and corporate governance disclosures for the companies within the Listed Peer Group. Mercer references policy fees for market comparison purposes as they presented the underlying fee structure of the peer companies, independent of the committees and roles that each individual director is accountable for.
- Mercer has referenced the Global Industry Classification Standard (GICS®) developed by Standard & Poor's and MSCI Barra as a basis for identifying the respective industries for potential comparator companies. The GICS structure consists of 11 sectors, 24 industry groups, 69 industries and 158 sub-industries.
- All remuneration data is presented in New Zealand Dollars unless otherwise indicated.
- All financial data including 6-months Market Capitalisation to 31 March 2023 and Most Recent Year End Revenue has been sourced from S&P Capital IQ as at 31 March 2023.

Ageing of market data

• Mercer does not apply 'ageing' to market data in our non-executive director fee reviews unless requested by the client. For this review, the data used in the analysis has not been aged.

Market positioning

• Fees are considered to be 'at' the relevant market reference point if FPH's incumbent fees were positioned within a ±15% range of the market data reference point.

Sample sizes

Mercer's approach requires at least five data points observed before presenting the 25th and 75th percentiles for each fee element. For the median, data is only presented if there at least four data points observed. For this review, we note that there were at least four data points observed for each fee element.

Committee fees

- In comparing FPH's committees to the Listed Peer Group, data from peer companies was matched based on the following classifications:
 - Audit and Risk Committee: Any committee with "Audit", "Risk" or "Finance" in the name.
 - People and Remuneration Committee: Any committee with "Remuneration" in the name, and if a company does not have a committee with "Remuneration" in the name, any committee that focuses on people or human resources (e.g., People Committee).

Page 10 Non-Executive Director Fee Benchmarking – Summary Report Fisher & Paykel Healthcare Corporation Limited 16 June 2023

 Quality, Safety and Regulatory Committee: Any committee with the following keywords in the name: "Quality", "Safety", "Regulatory", "Science", "Compliance".